Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 18;11:603450. doi: 10.3389/fendo.2020.603450

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2020 Zhang, Hu, Liu, Chen, Chen, Guo and Huang

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

The dose- and time-dependent effects of advanced glycation-bovine serum albumin (AGE-BSA) treatment on retinal microvascular pericyte (RMP) viability, moesin phosphorylation. (A, B) The effects of AGE-BSA treatment on RMP viability. (C) The effects of AGE-BSA treatment on RMP migration. (D, E) The effects of AGE-BSA treatment on moesin phosphorylation in RMPs. Data shown are representative of experimental and quantitative results. N = 3 independent experiments. *p < 0.05 vs. control, ^# p < 0.05 vs. BSA. Figure S2 confirmed the expression of moesin and ERM proteins in RMPs by positive staining of immunofluorent moesin or ERM protein in most cells.